.Gamma.-Hydroxybutyrate Sodium Salt
REM Sleep Behavior Disorder
Stanford UniversitySmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
12 Active assets in the REM Sleep Behavior Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ioflupane Weill Medical College of Cornell University | Phase 4 | BBB |
3-IODOBENZYLGUANIDINE (123I) Mayo Clinic | Phase 4 | BB |
Clonazepam Seoul National University Hospital | Phase 2 | B |
Idebenone Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2/3 | B |
Rasagiline Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2/3 | B |
View all 17 →
Same molecule, other indications
.Gamma.-Hydroxybutyrate Sodium Salt is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →